[Leukinferon in the treatment of patients with acute viral hepatitis b].
Leukinferon activity was studied in a controlled trial including 30 patients with acute viral hepatitis. The disease ran a moderate severity course in the majority of the patients. Leukinferon, a combined preparation of natural interferon and cytokines produced by virus-induced leukocytes, has marked immunomodulating properties at moderate antiviral activity. Leukinferon was administered intramuscularly for 10 days according to the following scheme: day 1-1 sample 3 times, day 2-1 ampule 2 times, day 3-10-1 ampule a day (overall 1 x 10(5) U of interferon). Due to leukinferon the symptoms of intoxication declined, hepatic biochemistry normalized more rapidly as well as the period of viremia and antigenemia. Positive clinical trends correlated with interferon system improvement and activation of natural killers. 6 months later complete recovery was registered in all leukinferon-treated subjects.
Golban
T D
TD
Cheshin
S G
SG
Kuznetsov
V P
VP
Farber
N A
NA
Beliaev
D L
DL
Kirzhner
L S
LS
Babaiants
A A
AA
Vasina
V I
VI
D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D016207:Cytokines / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000628:therapy*; D006801:Humans; D007273:Injections, Intramuscular; D007370:Interferon Type I / Q000627:therapeutic use*; D008297:Male; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D016207:Cytokines; D004338:Drug Combinations; D007370:Interferon Type I; C062252:leukinferon
Primenenie leĭkinferona v lechenii bolńykh ostrym virusnym gepatitom B.